BioPharmSignal logoBioPharmSignal

Biotech News

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Lyell Immunopharma (LYEL)Lyell ImmunopharmaFinancing

Closing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucel Smital Shah appointed Chief Financial and Business Officer SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma,

Open original release

Related news

SNDXSyndax Pharmaceuticals2026-06-04 11:00 EST

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

LYELLyell Immunopharma2026-05-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

IDYAIDEAYA Biosciences2026-06-10 20:05 EST

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

LYELLyell Immunopharma2026-06-01 12:00 EST

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

ARGXArgenx2026-05-06 20:01 EST

argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

LEGNLegend Biotech Corporation2026-06-18 01:21 EST

Legend Biotech Corporation Announces Pricing of Public Offering

LEGNLegend Biotech Corporation2026-06-17 20:29 EST

Legend Biotech Corporation Announces Proposed Public Offering

ANABAnaptysBio, Inc.2026-05-11 13:15 EST

Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors

GERNGeron2026-07-13 12:00 EST

Geron Announces Appointment of Chinmaya Rath as Chief Business Officer

REGNRegeneron Pharmaceuticals2026-05-15 18:09 EST

Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

View all latest news

Lyell Immunopharma

Lyell Immunopharma is a cell-therapy company focused on reprogramming T cells for durable cancer treatment. Its work centers on improving persistence and potency in cellular immunotherapy.

Recent company news

LYELLyell Immunopharma2026-06-01 12:00 EST

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

LYELLyell Immunopharma2026-05-12 12:00 EST

Lyell Immunopharma Announces Participation in May Investor Conferences

LYELLyell Immunopharma2026-05-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

LYELLyell Immunopharma2026-04-07 12:00 EST

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

LYELLyell Immunopharma2026-03-12 20:05 EST

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Stock data

Close
12.96 USD
Market cap
347.44M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States